ArticleNature genetics2015
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
222 citing papers in PubMed, 6 syntheses or guidelines pooled it, 370 citations in OpenAlex.
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review.American journal of clinical dermatology · 2023Pooled it
- Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Frontiers in oncology · 2022Pooled it
- The Progenetix oncogenomic resource in 2021.Database : the journal of biological databases and curation · 2021Pooled it
- Pooled it
- Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.Scientific reports · 2021Pooled it
- Primary Cutaneous Lymphomas and Lymphoproliferative Disorders: Current Insights for Classification and Management.Cancers · 2026Review
- Cutaneous T Cell Lymphoma: Targeting the Survival Network in Mycosis Fungoides and Sézary Syndrome.Cancers · 2026Review
- Review
- Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study.Blood neoplasia · 2026Article
- DNA methylation-based classification of hematolymphoid neoplasms.Blood advances · 2026Article
- Pathway-Centric Comparative Molecular Profiling of Sézary Syndrome and Primary Cutaneous CD8Cancers · 2026Article
- A Conversational Artificial Intelligence Framework for Comparative Pathway-Level Profiling of Sézary Syndrome and Primary Cutaneous CD8medRxiv : the preprint server for health sciences · 2026Article
- Mycosis Fungoides Is a Proliferation of Multiple Mutational Subclones.The Journal of dermatology · 2026Review
- Review
- Conversational Artificial Intelligence-Enabled Molecular Characterization of Sézary Syndrome Reveals Distinct Pathway-Level Alterations Compared with Non-Sézary Cutaneous T-Cell Lymphoma.medRxiv : the preprint server for health sciences · 2026Article
- Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review.Dermatology and therapy · 2026Review
- NF-κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma.Cancer science · 2026Article
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- Cellular and molecular aberrations generating new immunotherapeutic approaches in mycosis fungoides and Sézary syndrome: a comprehensive review of literature.Frontiers in immunology · 2026Review
162 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Sézary syndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4(+) T cells. Here we performed whole-exome sequencing of tumor-normal sample pairs from 25 patients with Sézary syndrome and 17 patients with other CTCLs. These analyses identified a distinctive pattern of somatic copy number alterations in Sézary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors. Mutation analysis identified a broad spectrum of somatic mutations in key genes involved in epigenetic regulation (TET2, CREBBP, KMT2D (MLL2), KMT2C (MLL3), BRD9, SMARCA4 and CHD3) and signaling, including MAPK1, BRAF, CARD11 and PRKG1 mutations driving increased MAPK, NF-κB and NFAT activity upon T cell receptor stimulation. Collectively, our findings provide new insights into the genetics of Sézary syndrome and CTCL and support the development of personalized therapies targeting key oncogenically activated signaling pathways for the treatment of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.